Article Information
History
- May 12, 2020.
Article Versions
- You are currently viewing Version 1 of this article (May 12, 2020 - 06:39).
- Version 2 (July 19, 2020 - 10:30).
- View Version 3, the most recent version of this article.
Copyright
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY 4.0 International license.
Author Information
- Peter Czuppon1,2,*,
- Florence Débarre1,
- Antonio Gonçalves3,
- Olivier Tenaillon3,
- Alan S. Perelson4,
- Jérémie Guedj3,†,* and
- François Blanquart2,3,†,*
- 1Institute of Ecology and Environmental Sciences of Paris, Sorbonne Université, UPEC, CNRS, IRD, INRA, 75252 Paris, France
- 2Center for Interdisciplinary Research in Biology, CNRS, Collège de France, PSL Research University, 75005 Paris, France
- 3Université de Paris, INSERM, IAME, F-75018 Paris
- 4Theoretical Biology and Biophysics, Los Alamos National Laboratory, Los Alamos, NM 87545, USA
- ↵*Corresponding author; e-mail: peter.czuppon{at}upmc.fr, jeremie.guedj{at}inserm.fr, francois.blanquart{at}college-de-france.fr
↵† Equal contribution.
Posted May 12, 2020.
Predicted success of prophylactic antiviral therapy to block or delay SARS-CoV-2 infection depends on the targeted mechanism
